ClinicalTrials.govpublic full text
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
infection, human immunodeficiency virus i, integrase inhibitor, hiv infection, raltegravir, gsk1349572, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 902166
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.